| Literature DB >> 28328930 |
Ewa Usarek1, Anna Barańczyk-Kuźma1,2, Beata Kaźmierczak1,2, Beata Gajewska1,2, Magdalena Kuźma-Kozakiewicz2,3.
Abstract
Quantitative polymerase chain reaction (qPCR) is the most specific and reliable method for determination of mRNA gene expression. Crucial point for its accurate normalization is the choice of appropriate internal control genes (ICGs). In the present work we determined and compare the expression of eight commonly used ICGs in lymphocytes from 26 patients with amyotrophic lateral sclerosis (ALS) and 30 control subjects. Peripheral blood mononuclear cells (PBMCs) before and after immortalization by EBV transfection (lymphoblast cell lines-LCLs) were used for qPCR analysis. LCLs were studied before and after liquid nitrogen cryopreservation and culturing (groups LCL1 and LCL2, respectively). qPCR data of 8 ICGs expression was analyzed by BestKeeper, NormFinder and geNorm methods. All studied genes (18SRNA, ACTB, B2M, GUSB,GAPDH, HPRT1, MT-ATP6 and RPS17) were expressed in PBMCs, whereas only first four in LCLs. LCLs cryopreservation had no effect on ICGs expression. Comprehensive ranking indicated RPS17 with MT-ATP6 as the best ICGs for qPCR in PBMCs of control and ALS subjects, and RPS17 with 18RNA or MT-ATP6 in LCLs from ALS. In PBMCs 18RNA shouldn't be used as ICG.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28328930 PMCID: PMC5362213 DOI: 10.1371/journal.pone.0174317
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Internal control assays on TaqMan® Array Plate.
| Gene name | Gene symbol | Assay ID |
|---|---|---|
| 18S ribosomal RNA | Hs99999901_s1 | |
| Actin, beta | Hs99999903_m1 | |
| Beta-2-microglobulin | Hs99999907_m1 | |
| Glucuronidase, beta | Hs99999908_m1 | |
| Glyceraldehyde-3-phosphate dehydrogenase | Hs99999905_m1 | |
| Hypoxanthine phosphoribosyltransferase 1 | Hs99999909_m1 | |
| Mitchondrially encoded ATP synthase 6 | Hs02596862_g1 | |
| Ribosomal protein S17 | Hs00734303_g1 |
Fig 1Ct values for candidate internal control genes (ICGs).
The expression was studied as described in Material and Method section and expressed as medians (25th-75th percentile).
Validation of internal control genes in PBMCs from control subjects.
| Gene | Stability value | Comprehensive ranking | |||
|---|---|---|---|---|---|
| BestKeeper | NormFinder | GeNorm | |||
| SD | r | ρ | M | ||
| 0.75 | 0.98 | 0.455 | 0.346 | 1.26 | |
| 0.73 | 0.96 | 0.565 | 0.346 | 1.71 | |
| 0.97 | 0.97 | 0.532 | 0.485 | 2.62 | |
| 1.13 | n/c | 0.541 | 0.578 | 3.91 | |
| 1.22 | n/c | 0.554 | 0.556 | 4.58 | |
| 1.39 | n/c | 0.727 | 0.613 | 6.32 | |
| 1.13 | n/c | 1.023 | 0.840 | 5.81 | |
| 1.61 | n/c | 2.336 | 1.239 | 8.00 | |
n/c–not calculated
Validation of internal control genes in PBMCs from ALS patients.
| Gene | Stability value | Comprehensive ranking | |||
|---|---|---|---|---|---|
| BestKeeper | NormFinder | GeNorm | |||
| SD | r | ρ | M | ||
| 0.58 | 0.91 | 1.542 | 0.580 | 1.19 | |
| 0.70 | 0.93 | 1.817 | 0.580 | 1.86 | |
| 1.81 | n/c | 1.331 | 1.876 | 2.94 | |
| 0.95 | 0.88 | 2.202 | 0.783 | 3.46 | |
| 1.24 | n/c | 2.806 | 1.318 | 4.68 | |
| 3.03 | n/c | 2.711 | 2.528 | 5.73 | |
| 3.63 | n/c | 3.054 | 2.971 | 7.00 | |
| 4.50 | n/c | 3.901 | 3.323 | 8.00 | |
n/c–not calculated
Validation of internal control genes in LCLs1 from ALS patients.
| Gene | Stability value | Comprehensive ranking | |||
|---|---|---|---|---|---|
| BestKeeper | NormFinder | GeNorm | |||
| SD | r | ρ | M | ||
| .83 | 0.66 | 0.678 | 0.938 | 1.26 | |
| .09 | n/c | 0.613 | 0.938 | 1.44 | |
| .83 | 0.69 | 1.046 | 1.126 | 2.08 | |
| .44 | n/c | 1.328 | 1.336 | 4.00 | |
n/c–not calculated
Validation of internal control genes in LCLs2 from ALS patients.
| Gene | Stability value | Comprehensive ranking | |||
|---|---|---|---|---|---|
| BestKeeper | NormFinder | GeNorm | |||
| SD | r | ρ | M | ||
| 1.24 | n/c | 0.302 | 0.348 | 1.26 | |
| 1.28 | n/c | 0.174 | 0.348 | 1.44 | |
| 1.26 | n/c | 0.400 | 0.398 | 2.62 | |
| 1.90 | n/c | 0.914 | 0.677 | 4.00 | |
n/c–not calculated